,
Funding for this research was provided by:
Alzheimer's Drug Discovery Foundation (RC-201711-2014067)
Article History
Received: 5 July 2018
Accepted: 10 September 2018
First Online: 15 October 2018
Ethics approval and consent to participate
: Ethics approval is not applicable to this protocol article.
: Not applicable.
: Dr. Tully reports funding from the National Health and Medical Research Council of Australia (Neil Hamilton Fairley—Clinical Overseas Fellowship #1053578).Prof. Anstey reports funding from the National Health and Medical Research Council of Australia Fellowship #1102694.Dr. Mahajan is supported by Early Career Fellowship from the National Health and Medical Research Council (NHMRC) and National Heart Foundation (NHF) of Australia. Dr. Mahajan reports that the University of Adelaide receives on his behalf lecture and/or consulting fees from Abbott and Medtronic.Prof. Seshadri reports that the Framingham Heart Study is supported by the following grants and contracts: NHLBI’s Framingham Heart Study (N01-HC-25195; HHSN268201500001I), NIA grants (R01 033193, U01 AG049505, R01 AG049607, R01 AG054076, U01 AG052409), and NINDS (R01NS017950, UH2 NS100605).The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.